RNXT Insider Trading
Insider Ownership Percentage: 9.13%
Insider Buying (Last 12 Months): $119,618.50
Insider Selling (Last 12 Months): $0.00
RenovoRx Share Price & Price History
Current Price: $1.27
Price Change: ▼ Price Decrease of -0.045 (-3.42%)
As of 07/1/2025 05:00 PM ET
RenovoRx Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
6/5/2025 | Ramtin Agah | Insider | Buy | 21,000 | $1.40 | $29,400.00 | 734,460 | |
4/15/2025 | Ramtin Agah | Insider | Buy | 15,000 | $0.90 | $13,500.00 | 1,113,460 | |
4/15/2025 | Shaun Bagai | CEO | Buy | 7,500 | $0.91 | $6,825.00 | 320,040 | |
4/11/2025 | Ramtin Agah | Insider | Buy | 20,000 | $0.80 | $16,000.00 | 1,098,460 | |
4/10/2025 | Ron Kocak | VP | Buy | 6,500 | $0.79 | $5,135.00 | 12,595 | |
4/9/2025 | Shaun Bagai | CEO | Buy | 10,000 | $0.83 | $8,300.00 | 312,540 | |
4/8/2025 | Laurence Marton | Director | Buy | 12,050 | $0.85 | $10,242.50 | 45,684 | |
4/8/2025 | Ramtin Agah | Insider | Buy | 26,000 | $0.84 | $21,840.00 | 1,048,460 | |
4/8/2025 | Ron Kocak | VP | Buy | 95 | $0.80 | $76.00 | 95 | |
4/7/2025 | Shaun Bagai | CEO | Buy | 10,000 | $0.83 | $8,300.00 | 302,540 | |
10/3/2023 | Angela Nelms | COO | Buy | 1,100 | $1.05 | $1,155.00 | 1,100 | |
RenovoRx Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
5/16/2025 | AWM Investment Company Inc. | 2,285,000 | $2.26M | 0.3% | N/A | 6.251% |  |
5/16/2025 | Alyeska Investment Group L.P. | 688,577 | $0.68M | 0.0% | N/A | 1.884% |  |
5/16/2025 | ADAR1 Capital Management LLC | 479,883 | $0.48M | 0.1% | +143.3% | 1.313% |  |
5/15/2025 | Corsair Capital Management L.P. | 187,700 | $0.19M | 0.0% | N/A | 0.514% |  |
5/14/2025 | Stonepine Capital Management LLC | 278,188 | $0.28M | 0.3% | N/A | 0.761% |  |
5/13/2025 | HighTower Advisors LLC | 40,000 | $40K | 0.0% | N/A | 0.109% |  |
5/9/2025 | Chicago Partners Investment Group LLC | 92,356 | $97K | 0.0% | N/A | 0.253% |  |
5/6/2025 | AIGH Capital Management LLC | 3,467,275 | $3.43M | 1.4% | N/A | 9.486% |  |
2/17/2025 | Citadel Advisors LLC | 37,757 | $49K | 0.0% | N/A | 0.157% |  |
2/13/2025 | Renaissance Technologies LLC | 64,900 | $84K | 0.0% | N/A | 0.270% |  |
2/13/2025 | ADAR1 Capital Management LLC | 197,250 | $0.25M | 0.1% | -37.4% | 0.822% |  |
11/16/2024 | Geode Capital Management LLC | 232,937 | $0.25M | 0.0% | +61.9% | 0.971% |  |
2/9/2024 | Nixon Peabody Trust Co. | 97,165 | $0.22M | 0.0% | N/A | 0.909% |  |
7/10/2023 | Level Four Advisory Services LLC | 15,000 | $34K | 0.0% | +50.0% | 0.148% |  |
6/5/2023 | Level Four Advisory Services LLC | 10,000 | $35K | 0.0% | N/A | 0.099% |  |
1/19/2023 | Affinity Capital Advisors LLC | 15,259 | $36K | 0.0% | +35.6% | 0.168% |  |
11/10/2022 | Cohen Lawrence B | 54,121 | $0.16M | 0.1% | -44.3% | 0.597% |  |
8/11/2022 | Cohen Lawrence B | 97,165 | $0.19M | 0.1% | +79.5% | 1.072% |  |
8/2/2022 | Bank of The West | 975,000 | $1.93M | 0.2% | N/A | 10.750% |  |
5/13/2022 | Cohen Lawrence B | 54,121 | $0.16M | 0.1% | N/A | 0.599% |  |
2/3/2022 | Cambridge Investment Research Advisors Inc. | 14,400 | $70K | 0.0% | -64.7% | 0.162% |  |
11/16/2021 | Schonfeld Strategic Advisors LLC | 20,569 | $0.13M | 0.0% | N/A | 0.245% |  |
11/16/2021 | Two Sigma Securities LLC | 17,944 | $0.11M | 0.0% | N/A | 0.214% |  |
11/12/2021 | Board of Trustees of The Leland Stanford Junior University | 60,863 | $0.37M | 0.0% | N/A | 0.726% |  |
11/2/2021 | Cambridge Investment Research Advisors Inc. | 40,850 | $0.25M | 0.0% | N/A | 0.487% |  |
Data available starting January 2016
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Read More on RenovoRx
Volume
54,611 shs
Average Volume
98,443 shs
Market Capitalization
$46.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.27
Who are the company insiders with the largest holdings of RenovoRx?